Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma

Por Erlich, R B, Kherrouche, Z, Rickwood, D, Endo-Munoz, L, Cameron, S, Dahler, A, Hazar-Rethinam, M, de Long, L M, Wooley, K, Guminski, A, Saunders, N A
Publicado em 2012

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

Por Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., Carlino, M. S., Hong, A., Long, G. V.
Publicado no Oncoimmunology (2016)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Por Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Publicado no Br J Cancer (2016)

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

Por Lear, J.T., Migden, M.R., Lewis, K.D., Chang, A.L.S., Guminski, A., Gutzmer, R., Dirix, L., Combemale, P., Stratigos, A., Plummer, R., Castro, H., Yi, T., Mone, M., Zhou, J., Trefzer, U., Kaatz, M., Loquai, C., Kudchadkar, R., Sellami, D., Dummer, R.
Publicado no J Eur Acad Dermatol Venereol (2017)